Genome Square
1 known investors
Genome Diagnostics develops blood-based liquid biopsy tests for cancer detection and monitoring, including a product for ovarian cancer recurrence detection and one for early pancreatic cancer detection. Its GenoME pipeline identifies DNA methylation and fragmentomic changes from liquid biopsy or tissue samples.
Investors · 1
Frequently asked questions
- What does Genome Square do?
- Genome Diagnostics develops blood-based liquid biopsy tests for cancer detection and monitoring, including a product for ovarian cancer recurrence detection and one for early pancreatic cancer detection. Its GenoME pipeline identifies DNA methylation and fragmentomic changes from liquid biopsy or tissue samples.
- Who are Genome Square's investors?
- Genome Square's investors include Clarendon Fund Managers Ltd..